Other languages ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Delayed Nasdaq Other stock markets 16:33:49 02/05/2024 BST			5-day change	1st Jan Change
2.01 ^USD	+0.50%		+2.55%	+1.52%

03-14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
03-13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProQR Therapeutics N : AGM 2024 AoA one-tier Board Dutch redline	04-23
ProQR Therapeutics N : AGM 2024 AoA one-tier Board Dutch clean	04-23
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	01-05
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	12-08
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	12-06
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	11-06
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V..	26/09/23
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23
ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member	17/05/23
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23
Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event	29/03/23
ProQR Therapeutics Wins Hearing on Key Patent for Axiomer	14/03/23
ProQR Therapeutics N.V. Announces Successful Defense of Key Axiomer(R) Patent Protecting Adar-Mediated RNA Editing	14/03/23
Proqr Therapeutics N.V. and Eli Lilly and Company Enters into an Amended and Restated Research and Collaboration Agreement	23/12/22
Top Midday Gainers	22/12/22
Eli Lilly : élargissement de l'accord avec ProQR	22/12/22
Eli Lilly Expands Genetic Medicines Partnership with ProQR Therapeutics	22/12/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Other languages

Filters